Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Slides:



Advertisements
Similar presentations
Where we stand in diabetes field ?
Advertisements

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association.
Implementing Diabetes Guidelines in the “Real World” Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard Medical School Senior Vice.
Canadian Diabetes Association Clinical Practice Guidelines Diabetes in the Elderly Chapter 37 Graydon S. Meneilly, Daniel Tessier, Aileen Knip.
Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G.
Hyperglycemia Management – Medication Therapy
Therapy of Type 2 Diabetes Mellitus: UPDATE
The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes
Therapy of Type 2 Diabetes Mellitus: UPDATE
1 NICE 2015 guidelines to help us treat T2 diabetes in 2016? Paul Newrick Consultant Physician WAHNHST 2016.
What's New in Basal Insulin for Diabetes
Medications Used in the Treatment of Diabetes Mellitus
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
15th MGSD Congress April, 2017
James Thrasher, MD  The American Journal of Medicine 
Copyright © 2015 by the American Osteopathic Association.
From: Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesA Systematic Review and Meta-analysis Ann Intern Med.
Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.
Applying Data to Practice
Luigi F. Meneghini, MD, MBA  The American Journal of Medicine 
Stuart A. Ross, MB CHB, FRACP, FRCP(C) 
ADA-Standard of Medical Care-2017 Updates to standards of medical care in diabetes 2016 Diabetes Care 2017;40(Suppl. 1):S1–S138.
Special Consideration in Insulin Therapy
بنام خداوند جان و خرد Long-Acting Glucagon-Like Peptide 1 Receptor Agonists A review of their efficacy and tolerability M. Siavash Professor of endocrinology.
Global Projections for Diabetes:
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Updates on Outcomes for Novel T2D Therapies
How Early Should Basal Insulin Be Used in T2D Management?
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Diabetes management (Updated guidelines)
Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.
Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use  David M. Kendall, MD, Robert M. Cuddihy, MD,
Emerging CVOT Data and Clinical Application
GLP-1 Receptor Agonists: How Early Is Appropriate?
Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm  Timothy Bailey, MD  The American.
James Thrasher, MD  The American Journal of Medicine 
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic therapy in type 2 diabetes: general recommendations
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).
Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Individualizing Insulin Therapy in the Management of Type 2 Diabetes
Predicted and observed HbA1c levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.
Approach to starting and adjusting insulin in type 2 diabetes.
Insulin Innovation.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Patient Selection for Modern T2D Agents
Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.
Improving Effective Basal Insulin Use in Clinical Practice
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.
Evolution of Insulin: From Human to Analog
Emerging Combination Injectable Therapy A New Era in Diabetes Care
ADA/EASD general recommendations for type 2 diabetes management (1).
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
Glucose-lowering medication in type 2 diabetes: overall approach.
Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).
ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine,
Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.
Antihyperglycemic therapy in adults with type 2 diabetes
An insulin simplification regimen: from multiple injections to once-daily long-acting (basal) insulin plus noninsulin agents. *Basal insulins: glargine.
Glucose-lowering medication in type 2 diabetes: overall approach.
Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.
Presentation transcript:

Antihyperglycemic therapy in type 2 diabetes: general recommendations. Antihyperglycemic therapy in type 2 diabetes: general recommendations. The order in the chart was determined by historical availability and the route of administration, with injectables to the right; it is not meant to denote any specific preference. Potential sequences of antihyperglycemic therapy for patients with type 2 diabetes are displayed, with the usual transition moving vertically from top to bottom (although horizontal movement within therapy stages is also possible, depending on the circumstances). DPP-4-i, DPP-4 inhibitor; fxs, fractures; GI, gastrointestinal; GLP-1 RA, GLP-1 receptor agonist; GU, genitourinary; HF, heart failure; Hypo, hypoglycemia; SGLT2-i, SGLT2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione. *See original source for description of efficacy categorization. §Usually a basal insulin (NPH, glargine, detemir, degludec). Adapted with permission from Inzucchi et al. Diabetes Care 2015;38:140–149. American Diabetes Association Clin Diabetes 2017;35:5-26 ©2017 by American Diabetes Association